Meet the woman leading vaccine innovation in Senegal to fight Rift Valley fever and empower Africa’s next generation of ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

An exciting collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging artificial intelligence (AI) to aid the development of T cell ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

As bird flu continues to threaten animals and public health, the U.S. government has stepped up its response. Experts says it ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

A collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging ...

Mexico’s first female president On October 1, Claudia Sheinbaum became Mexico’s first female and Jewish president, making history. In a nation where women were granted the right to vote only in 1953, ...

“Successful self-replication under no human assistance is the essential step for AI to outsmart [humans], and is an early ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.